公开(公告)号：US20240336594A1

公开(公告)日：2024-10-10

申请号：US18576708

申请日：2022-06-24

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Bang FU ,  Yinlong LI ,  Wei REN ,  Qichao SHEN ,  Guolong DU ,  Xiaojun ZHOU ,  Yun SUN ,  Yuzhen ZHOU ,  Xiao SUN ,  Weidong CAI ,  Xiangyong LIU ,  Lieming DING ,  Jiabing WANG

IPC: C07D401/14 ,  A61K31/167 ,  A61K31/18 ,  A61K31/423 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/538 ,  C07C237/40 ,  C07C311/32 ,  C07C317/32 ,  C07C323/33 ,  C07D205/12 ,  C07D213/56 ,  C07D263/56 ,  C07D265/36 ,  C07D401/04 ,  C07D401/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107

CPC classification number: C07D401/14 ,  A61K31/167 ,  A61K31/18 ,  A61K31/423 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/538 ,  C07C237/40 ,  C07C311/32 ,  C07C317/32 ,  C07C323/33 ,  C07D205/12 ,  C07D213/56 ,  C07D263/56 ,  C07D265/36 ,  C07D401/04 ,  C07D401/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04 ,  C07D487/08 ,  C07D491/048 ,  C07D491/107

Abstract: A compound of formula I and a use thereof as an MALT1 inhibitor, and a pharmaceutical composition containing the compound. The compound can be used to treat diseases or disorders such as cancer.

公开(公告)号：US20240174681A1

公开(公告)日：2024-05-30

申请号：US17907117

申请日：2021-03-26

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Jinheng GAO ,  Xiaofeng XU ,  Liang CHEN ,  Zhongxin SUN ,  Yun ZHANG ,  Xiangyong LIU ,  Lieming DING ,  Jiabing WANG

IPC: C07D487/14 ,  A61K31/519 ,  A61P35/00

CPC classification number: C07D487/14 ,  A61K31/519 ,  A61P35/00

Abstract: The present invention relates to a crystalline form and/or maleate, phosphate, L-tartrate, and adipate of the compound represented by the structural formula I, and various crystalline forms of various salt forms, and preparation methods and applications thereof.

公开(公告)号：US20230133169A1

公开(公告)日：2023-05-04

申请号：US17768807

申请日：2020-10-13

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Xiangyong LIU ,  Changyong QIU ,  Guolong DU ,  Qichao SHEN ,  Mengqiang LIU ,  Haitong SHENG ,  Lieming DING ,  Jiabing WANG

IPC: C07D239/48 ,  C07D403/10

Abstract: Provided are the compounds of Formula I, a method for using these compounds as an EGFR inhibitor, and a pharmaceutical composition comprising the compounds. The compound is used for treatment, prevention or amelioration of diseases or conditions such as cancer or infection.

公开(公告)号：US20220002307A1

公开(公告)日：2022-01-06

申请号：US17280309

申请日：2019-09-26

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Jinheng GAO ,  Zhongxin SUN ,  Yun ZHANG ,  Xiaofeng XU ,  Xiangyong LIU ,  Jiabing WANG ,  Lieming DING

IPC: C07D487/14 ,  C07D471/04 ,  C07D471/14 ,  C07D491/147 ,  C07D491/22 ,  C07D495/14 ,  C07D513/14 ,  A61P35/00

Abstract: Disclosed is a compound as a fibroblast growth factor receptor 4 (FGFR4) inhibitor (as shown in formula (I)), and a pharmaceutical composition thereof and a preparation method therefor, as well as the use of same in the treatment of FGFR4-mediated diseases. The above-mentioned compounds act by participating in a number of processes, such as regulating cell proliferation, apoptosis, migration, neovascularization.

公开(公告)号：US20210130353A1

公开(公告)日：2021-05-06

申请号：US16488899

申请日：2018-02-27

Applicant: BETTA PHARMACEUTICALS CO., LTD.

Inventor： Xiaofeng XU ,  Jiabing WANG ,  Lieming DING ,  Xiangyong LIU

IPC: C07D471/14 ,  C07D519/00 ,  A61P35/00

Abstract: An azatricyclic compound (as represented by formula I) which acts as an inhibitor of fibroblast growth factor receptors (FGFR), as well as a pharmaceutical composition thereof, a preparation method, and a use therefor in the treatment of FGFR-mediated diseases. The azatricyclic compound exerts an effect by means of participating in the regulation of a plurality of processes such as cell proliferation, apoptosis, migration, neovascularization, and the like. AA %%% Formula (I).

公开(公告)号：US20210040118A1

公开(公告)日：2021-02-11

申请号：US17041455

申请日：2019-04-03

Applicant: BETTA PHARMACEUTICALS CO., LTD

Inventor： Yiqian WANG ,  Bang FU ,  Yao ZHANG ,  Xiangyong LIU ,  Jiabing WANG ,  Lieming DING

IPC: C07D513/04 ,  C07D417/14 ,  C07D495/04 ,  C07D471/04 ,  C07D277/56 ,  C07D487/04 ,  C07D271/10 ,  C07D519/00 ,  C07D498/04 ,  C07D285/12

Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.